The true semaglutide cost in 2026 spans more than a 20x range — and one seller proves it on a single menu. altRx advertises compounded semaglutide at $89 a month and brand-name Wegovy at $1,579 a month. Same website. Same active ingredient on the label. A 17x gap. Across the seven sellers we priced, compounded semaglutide runs $84 to $299 a month, brand-name Wegovy through telehealth runs $149 to $399 plus membership fees, and retail brand listings hit $999 to $1,999.
Every number below comes from provider websites and press materials pulled in July 2026, or from third-party pricing reports where sellers hide the ball. One rule before the map: compounded semaglutide is not FDA-approved — no version of it, from any pharmacy. The FDA has flagged dosing errors and quality concerns with unapproved GLP-1 drugs, and two companies in this guide have 2026 FDA warning letters in their corporate family. The cheap end of this market demands the most scrutiny, and that is exactly where we point the flashlight.
The Real Semaglutide Cost Map: $84 to $1,999 a Month
Three channels sell the same drug name at wildly different prices. Here is the full 2026 board, verified seller by seller.
| Channel | Monthly cash price | What we verified |
|---|---|---|
| Compounded semaglutide (not FDA-approved) | $84–$299 | altRx $89 ($75 prepaid yearly); Trinity Meds $99 ($84 prepaid); bmiMD $99–$129; Noom Med $129 first month, then $249–$279; MEDVi $179, then $299 |
| Brand-name via telehealth, cash | $149–$399 + membership | Wegovy pill from $149 at Ro and Hers; Wegovy pen $199–$399; both add a $39-then-$149/mo membership |
| Brand-name retail, no program | $900–$1,999 | Ro lists cash Ozempic at $900–$1,100; Trinity Meds funnel lists Ozempic at $999; altRx lists Ozempic $1,149 and Wegovy $1,579; MEDVi press materials list Ozempic at $1,999 |
Three patterns jump out. First, the compounded floor keeps sinking — $84 to $99 a month flat — but the cheapest sellers carry the ugliest complaint records. Second, telehealth brand programs cluster tightly: $149 for pills, $199 to $399 for pens, then membership fees stack $149 a month on top. Third, the retail column exists mostly to make the other two look good. Nobody should pay $1,579 for Wegovy when the same sellers offer cheaper verified paths.
One more wrinkle: prepay traps. The $99 headline at bmiMD requires $1,188 billed at once for 12 months. Trinity Meds hits $84 only on a 12-month plan. altRx hits $75 the same way. Flat monthly rates without commitment run $129 to $299.
Why Does Semaglutide Cost 15x More in Some Channels?
The molecule name is the same. The price is not. Three forces explain the spread.
Force one: brand economics. Novo Nordisk spent years and clinical trials getting Wegovy approved — in the STEP 1 trial, adults on 2.4 mg weekly lost an average of 14.9% of body weight over 68 weeks, versus 2.4% on placebo. FDA approval, trial data, and manufacturing oversight are priced into every pen. That is a big part of the $999-to-$1,999 retail column.
Force two: manufacturer-direct discounting. Since Novo Nordisk and Eli Lilly opened direct cash channels, telehealth programs plug straight in. Ro says its cash prices match NovoCare, LillyDirect, and TrumpRx — which is how an FDA-approved Wegovy pill lands at $149 the first month instead of four figures. This channel did not exist at scale two years ago. It is the single biggest reason the 2026 semaglutide cost picture looks better than 2024’s.
Force three: compounding. A compounding pharmacy produces its own version of the active ingredient for a patient-specific prescription. No FDA approval, no trials to recoup, no brand premium — so the price drops to $84–$299. But be plain about what you get: the FDA has never evaluated any compounded semaglutide for safety, effectiveness, or quality. The sellers’ own disclaimers say so. The discount is not free; it is paid in reduced oversight. That is why we treat a 15x price gap as a risk signal, not just a bargain.
Now the sellers, ranked. Scores come from our documented research process — pricing verification, fine-print analysis, and complaint records.
1. Ro — Brand-Name Semaglutide at Manufacturer-Direct Prices
Score: 8.8/10 (Very Good). Ro is the price-transparency benchmark of this list. As of July 2026 its weight-loss menu is 100% FDA-approved brand-name drugs — Wegovy pen, the new Wegovy pill, and off-label Ozempic — sourced through Novo Nordisk’s NovoCare channel and Lilly integrations. Zero compounded semaglutide appears on its current pricing page.
The cost weapon is insurance support. Ro checks your coverage free, and its concierge files prior-authorization paperwork — a 2-to-3-week process that can cut your medication cost to a copay. No compounded seller can touch that. Ro covers all 50 states plus D.C.
Pricing Structure
| Ro line item | First month | Ongoing |
|---|---|---|
| Membership (required) | $39 | $149/mo, or about $74/mo prepaid annually |
| Wegovy pill | $149 | $199–$299/mo |
| Wegovy pen | $199 | $199–$399/mo |
| Ozempic, cash at pharmacy | $900–$1,100/mo | $900–$1,100/mo |
Do the honest math: the cheapest first month is $188 (pill plus membership), and ongoing cash cost runs $348 to $548 a month depending on dose and membership plan. Ro’s own FAQ confirms Wegovy prices rise at higher doses. The membership is charged only if you are found eligible, and an annual prepay saves up to $900 a year, per Ro.
Pros & Cons
Pros: Every drug is FDA-approved — no gray zone. Cash prices track manufacturer-direct channels, and the insurance concierge can collapse your drug cost to a copay. Membership and medication bill separately, so you see each charge. Cons: There is no budget lane — realistic cash totals of $348+ a month beat retail but triple the compounded floor. Prices climb with dose, topping at $399 for the pen before membership. And its record is mixed: BBB B rating with 610 complaints, and a Trustpilot around 3.7 stars per third-party citations, with recurring membership-billing gripes.
2. Noom Med — The Mid-Priced Compounded Play With 503B Sourcing
Score: 8.7/10 (Very Good). Noom Med sells compounded semaglutide at a middle price with the best sourcing disclosure in the compounded field: it states its drug comes from an FDA-regulated 503B outsourcing facility using sterile cGMP production, per its 2024 announcement. A 503B facility registers with the FDA and gets FDA inspections — a higher oversight tier than the unnamed pharmacies elsewhere on this list. Still not FDA-approved, and Noom’s own disclaimer says exactly that.
The price includes the full Noom app, coaching, and behavior-change curriculum. The company has operated since 2008 and holds a BBB A+ rating, accredited since 2021 — the strongest accreditation of any compounded seller here.
Pricing Structure
| Noom Med plan | First month | Ongoing |
|---|---|---|
| Compounded semaglutide (GLP-1Rx) | $129 | $249–$279/mo, billed quarterly |
| Microdose semaglutide | $79 | $179–$199/mo, billed quarterly |
| Brand-name path (drug billed separately) | $39 | $99/mo + medication via insurance or cash |
Two catches. After month one, billing arrives in quarterly lumps of roughly $537 to $837. And in July 2026 Noom’s pricing hub showed $249/month while its own product page showed $279/month for the same plan — an on-site inconsistency worth screenshotting before checkout. Compounded plans are unavailable in Alabama, Louisiana, and Mississippi, and Noom does not state whether cost changes as your dose titrates.
Pros & Cons
Pros: All-inclusive pricing with real coaching bundled. The $79 microdose tier is the cheapest legitimate entry point in this ranking. 503B sourcing disclosure beats every compounded rival. Its Taper-Off Guarantee promises a year of free Noom or medication discounts if weight returns within 18 months after a 12-month course with its taper protocol, per Noom’s announcement. Cons: The promo cliff is steep — $129 becomes $249 to $279. Quarterly billing means single charges near $837. No published refund policy beyond cancel-anytime, and its two prices for one plan do not inspire confidence.
3. Hers — Brand-Name From $149, Plus a $149 Membership
Score: 8.5/10 (Very Good). Hers learned its pricing lesson the hard way. The FDA sent it a warning letter on September 9, 2025 for false or misleading marketing of compounded semaglutide — which is not FDA-approved — and Novo Nordisk sued its parent company in February 2026 over those compounded products. By March 2026, Hers restricted compounded semaglutide to medical necessity. Its 2026 model is brand-name first: Wegovy pill and pen, Ozempic, and Zepbound formats for women in all 50 states.
Visits are asynchronous — no video call, no labs in most states — with provider review typically within 24 hours. Insurance is not accepted; everything is cash.
Pricing Structure
| Hers line item | Price |
|---|---|
| Membership (required) | $39 first month, then $149/mo |
| Wegovy pill / Ozempic pill | From $149/mo |
| Wegovy pen / Ozempic pen | From $199/mo |
| Zepbound vial or KwikPen | From $299/mo |
| Retail Zepbound / Mounjaro | $1,899/mo |
Per third-party pricing reports from July 2026, the cheapest realistic first month totals about $193 including $5 shipping, and ongoing cost lands near $303 a month. Those “from” prices matter: medication cost rises with dose, and Hers does not publish full dose-by-dose pricing. Refunds are nearly nonexistent — only unshipped initial orders canceled within 48 hours qualify, and canceling medication does not cancel the membership.
Pros & Cons
Pros: FDA-approved brand-name semaglutide from $149 a month — a fraction of the $1,899 retail figure on its own pricing page. Both pill and pen formats. Backed by NYSE-listed Hims & Hers with a BBB A+ rating and roughly 3.8/5 across ~7,000 reviews, per third-party reporting. Cons: The membership does not include or guarantee a prescription — its own site says so — yet costs $149 a month forever. True ongoing cost is medication plus membership, roughly $303+. The FDA letter and the active Novo Nordisk lawsuit are recent history, not ancient.
4. bmiMD — The $99 Flat-Price Value Play
Score: 8.2/10 (Very Good). bmiMD is our pick for cheapest credible compounded semaglutide. The New York telehealth company (operating since late 2022) bundles the same-day telehealth visit, medication, unlimited provider messaging, and shipping into one flat price that its product pages promise stays the same at every dose. No membership fee. No insurance needed — or accepted.
The trust picture is mid-tier but honest: BBB C+ with 38 complaints, and a Trustpilot around 4 stars across roughly 800+ reviews per July 2026 search snapshots. It also publishes third-party quality-testing claims — potency within ±10%, USP 797 sterility, endotoxin testing — though its compounding pharmacies stay unnamed. And to be plain: compounded semaglutide here, like everywhere, is not FDA-approved.
Pricing Structure
| bmiMD semaglutide plan | Monthly rate | Billed as |
|---|---|---|
| 12-month | $99/mo | $1,188 upfront |
| 6-month | $109/mo | $654 upfront |
| 3-month | $119/mo | $357 upfront |
| Month-to-month | $129/mo | Monthly |
Your card is authorized, not charged, until a provider approves you — a fairer setup than pay-first rivals. But read the exit rules: a $50 cancellation fee applies between intake approval and pharmacy processing, and once the pharmacy processes your order, all sales are final. No refunds on partially used subscription periods.
Pros & Cons
Pros: The best verified dollar-per-month rate from a seller without an F rating or an FDA warning letter: $99 to $129 a month, flat at every dose. No-charge-until-approved billing. HSA/FSA and buy-now-pay-later accepted; free subscription shipping. Cons: The $99 rate demands $1,188 upfront — a lot of trust in a company with a C+ BBB grade. Pharmacies are unnamed with no 503A/503B disclosure. Complaints cite refund run-arounds and support delays.
5. MEDVi — $179 Teaser, $299 Reality
Score: 7.6/10 (Good). MEDVi advertises one of the better first-month prices in compounding — then the bill grows. Its compounded semaglutide injection costs $179 the first month and $299 on every refill, a 67% jump, per the company’s own January 2026 press materials. The flat $299 does not rise with dose, which helps at the top of titration. MEDVi’s standout is form factor: it sells daily dissolvable semaglutide tablets from $249 the first month — rare among GLP-1 telehealth platforms — though tablet refill prices go unpublished, with third parties citing up to $369.
The reputation split is the widest we track: Trustpilot around 4.4 stars across ~14,000 reviews, against a BBB F rating with 662 complaints, 100 of them unanswered.
Pricing Structure
| MEDVi plan | First month | Refills |
|---|---|---|
| Compounded semaglutide injection | $179 | $299/mo flat |
| Compounded semaglutide tablets | $249 | Unpublished; up to $369 per third-party reports |
| Brand Wegovy/Zepbound path | $99 membership + drug cost | $99 membership + drug cost |
| Brand Ozempic | $1,999/mo per press materials | — |
One review site reports MEDVi bills on a 28-day cycle — about 13 charges a year instead of 12, which quietly adds a fourteenth week of cost. Refunds are generally unavailable once medication is dispensed for a cycle. Recurring complaints allege unauthorized auto-renewal charges, often $399, and cancellation friction.
Pros & Cons
Pros: All-inclusive compounded pricing — consult, medication, expedited shipping, support — with no membership fee on compounded plans. Names its compounding pharmacies (Triad Rx, RedRock, Beaker), which most rivals refuse to do. Oral tablets exist for the needle-averse. Cons: The $179-to-$299 jump makes the ad price misleading as a planning number. The F BBB rating and 662 complaints are hard to explain away. Compounded product is not FDA-approved, and insurance is not accepted.
6. Trinity Meds — $99 Advertised, But Which Price Is Real?
Score: 6.8/10 (Fair). Trinity Meds posts genuinely low flat pricing: compounded semaglutide at $99 a month, sliding to $84 a month on a 12-month plan — with consult, prescription, shipping, and check-ins included, and the same price at every dose. It even names its four dispensing pharmacies (Belmar, Strive, Epiq Scripts, Casa Pharma Rx), a transparency point most competitors skip.
Then the contradictions start. The company’s own funnel page lists semaglutide from $159 a month — 61% higher than its homepage — and its March 2026 press release quotes the $159 figure too. Its FAQ claims all-50-states service while its formal terms say certain states. Which page do you believe? On a cost guide, that inconsistency is disqualifying for a top-five spot.
Pricing Structure
| Trinity Meds semaglutide plan | Monthly rate |
|---|---|
| Month-to-month (main site) | $99/mo |
| 3-month plan | $94/mo |
| 6-month plan | $89/mo |
| 12-month plan | $84/mo |
| Same drug on its own funnel page | From $159/mo |
| Brand Ozempic (funnel, limited supply) | From $999/mo |
The fine print bites: per terms quoted in the company’s own press release, consult fees are non-refundable, “all sales of prescription products are final,” and plans auto-renew until you cancel. The funnel says first delivery typically takes 1.5 to 3 weeks.
Pros & Cons
Pros: The $84/month 12-month rate is the lowest flat compounded price we verified anywhere. Truly all-inclusive, FSA-eligible, free tracked shipping, and named pharmacies. Cons: Trustpilot sits at 2.1/5 across 119 reviews with 65% one-star, citing charges after cancellation and unresponsive support. Its operating entity, Trinity Healthcare Supply, LLC, matches the recipient of a June 8, 2026 FDA warning letter issued over the affiliated altRx brand’s GLP-1 marketing. The compounded product is not FDA-approved, and no BBB profile exists to check.
7. altRx — The $89 Headline With an F Rating
Score: 6/10 (Fair). altRx owns the number in this page’s title — twice. Compounded semaglutide at $89 a month (struck through from $199), and brand Wegovy at $1,579 a month. It is the cheapest advertised semaglutide on this list and the most expensive, on one menu. A 12-month commitment drops the compounded rate to $75 a month, flat at every dose, all 50 states, no membership fee.
Here is why it ranks last anyway. The FDA sent altRx a warning letter on June 8, 2026 for misbranding and misleading claims about compounded semaglutide and tirzepatide on its website. Its BBB file — opened only in May 2026 — already shows an F rating with 39 complaints the business failed to answer. And Trustpilot reviewers repeatedly allege a bait-and-switch: sign up at $89, get billed $189 to $199 in later cycles. Trustpilot has also removed fake reviews for this company.
Pricing Structure
| altRx product | Advertised price |
|---|---|
| Compounded semaglutide | $89/mo (strikethrough $199); $75/mo on 12-month plan |
| Compounded tirzepatide | $149/mo (strikethrough $299) |
| Brand Ozempic | From $1,149/mo |
| Brand Zepbound | From $1,249/mo |
| Brand Wegovy | From $1,579/mo |
Refunds exist only for medical ineligibility at the initial consult or verifiable billing errors, within a 28-day window. Once an order is approved or shipped, no refunds. Its compounded drugs come from 503A pharmacies and are not FDA-approved — altRx’s own disclaimer concedes they have not been evaluated for safety, efficacy, or quality.
Pros & Cons
Pros: The lowest advertised semaglutide price in this guide at $89/month, with flat dosing, free shipping, named 503A pharmacies, and a pause-anytime membership. Brand-name options exist for those who want them. Cons: An FDA warning letter, an F BBB rating, and 51% one-star Trustpilot reviews — all inside the company’s first year of records. The alleged $89-to-$199 billing pattern attacks the very thing the price promises. We score it 6/10 and suggest you treat the headline number as unverified until your third bill clears.
Is $89 Semaglutide Too Good to Be True?
Look at the pattern in this ranking: the price floor and the complaint ceiling are the same companies. The $89 seller carries an F BBB rating and a June 2026 FDA warning letter. The $99-to-$84 seller posts a 2.1-star Trustpilot and shares a legal entity with that same warning letter. Meanwhile bmiMD, at a nearly identical $99 to $129, holds a C+ and roughly 4 stars. The extra $10 to $40 a month is not buying a different molecule — it is buying a company that answers its complaints.
There is also a legal layer under every low price. Compounded semaglutide occupies a narrow lane of federal law, and that lane tightened after the shortage ended. None of it is FDA-approved, and the FDA has warned about dosing errors with unapproved GLP-1 products sold online. Before any $89 checkout, read our plain-English breakdown of whether compounded GLP-1s are legal — it explains 503A versus 503B pharmacies and what the 2025-2026 enforcement wave changed.
Quick gut check: if a seller’s advertised price, funnel price, and press-release price disagree — as Trinity Meds’ $99 versus $159 do — assume the higher number until your own receipt proves otherwise.
How Does the Dose Schedule Change Your Semaglutide Bill?
Semaglutide is not one price because semaglutide is not one dose. Wegovy titrates from 0.25 mg weekly up to 2.4 mg over months, per its FDA label — and in some channels, your bill climbs the ladder with you. Ro’s pen runs $199 at entry doses and up to $399 at the top. Hers publishes “from” prices that rise with dose and never shows the full grid. Budget for your month-six dose, not your month-one dose.
Flat-price sellers flip that math. bmiMD, Trinity Meds, altRx, and MEDVi (after month one) charge the same rate at 2.4 mg as at 0.25 mg — which is why compounded pricing looks even cheaper late in titration than early. A $299 MEDVi refill versus a $399 top-dose Ro pen plus $149 membership is a $249/month gap at maintenance dose.
Map your own escalation timeline with our Wegovy dosage schedule guide, then price the dose you will actually be taking in month six. That single step prevents the most common budgeting mistake we see: signing up at the intro dose price and getting shocked at maintenance.
Will Semaglutide Prices Keep Falling in 2026?
The two big forces are pulling in opposite directions. Brand prices are falling: manufacturer-direct cash channels pushed the FDA-approved Wegovy pill to $149 a month through telehealth — unthinkable when retail listings sat near $1,999. If that trend holds, the case for compounded copies weakens every quarter.
Compounded prices, meanwhile, sit on shrinking legal ground. The FDA declared the semaglutide shortage resolved in February 2025, mass-compounding grace periods lapsed in spring 2025, and enforcement followed — a wave of warning letters to compounded GLP-1 sellers in September 2025, with letters still landing in June 2026 (see altRx above). Fewer legal sellers usually means less price competition, not more. The $84-to-$99 floor could rise or vanish with the next enforcement round. Our guide to the GLP-1 shortage and compounding in 2026 tracks exactly where that line sits now.
Our advice: never prepay 12 months to a compounded seller purely to lock a rate. bmiMD’s $1,188 or altRx’s $75/month commitment assumes the seller — and its legal lane — both exist in month twelve. That is not a bet this market has earned.
What Should You Budget for a Full Year?
Semaglutide is a long-haul treatment — STEP 1 measured its 14.9% average weight loss over 68 weeks, not 68 days — so annual math beats monthly math. Here is realistic year-one cash cost at the verified prices above, before any insurance.
| Seller and plan | Realistic year-one cash |
|---|---|
| altRx, 12-month commitment | About $900 — if billing matches the ad |
| Trinity Meds, 12-month plan | About $1,008 |
| bmiMD, 12-month prepaid | $1,188 |
| Noom Med, standard plan | About $2,868 ($129 + 11 months near $249) |
| Hers, Wegovy pill + membership | About $3,526 per third-party pricing reports |
| MEDVi, injection refills | About $3,767 — more on a 28-day cycle |
| Ro, Wegovy pill + monthly membership | About $4,016 and up, dose-dependent |
Read that table with both eyes. The cheapest column belongs to sellers with F ratings, 2-star reviews, or FDA letters — and none of their products are FDA-approved. The most expensive rows buy FDA-approved medication, and Ro’s row can collapse to membership plus a copay if your insurance approves prior authorization, which would make it the cheapest real-world option on this page. Full scoring criteria — pricing verification, fine print, complaint records — live at how we rank.
The honest bottom line: a safe cash budget for FDA-approved semaglutide in 2026 is $3,500 to $4,000 a year; the compounded floor is a third of that, paid for in oversight you give up. Talk to your own doctor before choosing either lane — and whatever you pick, screenshot the checkout page. In this market, the receipt is the only price that counts.